Pharmaceuticals

Regeneron Telix Radiopharma Deal Targets Cancer Therapies

Yuvraj — Wed, 15 Apr 2026 05:04:32 +0000

Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with Telix’s isotope delivery platforms, targeting multiple solid tumor indications. Both companies will equally share development costs […]

The post Regeneron Telix Radiopharma Deal Targets Cancer Therapies first appeared on World Pharma Today.

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Yuvraj — Sat, 11 Apr 2026 08:39:47 +0000

Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug manufacturing deals increasingly favoring European markets over the United States. The shift underscores how companies are […]

The post Drug Manufacturing Deals Shift to Europe Despite Tariffs first appeared on World Pharma Today.

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Yuvraj — Tue, 07 Apr 2026 06:53:33 +0000

Neurocrine Biosciences is close to securing a more than $2.5bn acquisition of Soleno Therapeutics, the developer of a treatment for a rare genetic form of obesity. The talks, described as advanced, highlight how midsized drugmakers are increasingly pursuing strategic deals to expand their portfolios. Neurocrine, known for its focus on neuropsychiatric medicines, is seeking to […]

The post Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition first appeared on World Pharma Today.

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Yuvraj — Tue, 07 Apr 2026 06:21:05 +0000

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, in a move that significantly expands its presence in immunology and rare diseases. The Biogen to Acquire Apellis deal stands among the company’s largest transactions to date, reinforcing its efforts to diversify beyond its core therapeutic areas. As part of the agreement, the […]

The post Biogen to Acquire Apellis for $5.6 Billion in Major Deal first appeared on World Pharma Today.

The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement

Yuvraj — Mon, 06 Apr 2026 08:17:20 +0000

Why Field Execution Must Evolve Field execution — how pharma companies organize, direct, and deliver commercial and medical interactions with healthcare professionals (HCPs), prescribers, and institutional decision-makers (collectively, “customers”) — is a major contributor to commercial success. Accordingly, over the past decade, companies have invested heavily in sales force effectiveness, key account management, omnichannel strategies, […]

The post The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement first appeared on World Pharma Today.

Trump Announces 100% US Pharma Tariffs for Patented Drugs

Yuvraj — Sat, 04 Apr 2026 08:55:16 +0000

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements with the US government or committed to establishing manufacturing operations domestically. Positioned as a national security […]

The post Trump Announces 100% US Pharma Tariffs for Patented Drugs first appeared on World Pharma Today.

UK-US Pharma Trade Deal Drives Tariff Cuts, Pricing Shift

Yuvraj — Sat, 04 Apr 2026 08:03:56 +0000

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework first outlined in December and signed in June 2025, establishes zero tariffs on pharmaceutical exports to […]

The post UK-US Pharma Trade Deal Drives Tariff Cuts, Pricing Shift first appeared on World Pharma Today.

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Yuvraj — Fri, 03 Apr 2026 08:47:22 +0000

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic areas beyond its current core focus, particularly within neuroscience. Under the terms announced Tuesday, Lilly will […]

The post Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal first appeared on World Pharma Today.

Novartis $2bn Excellergy Acquisition Boosts Allergy Pipeline

Yuvraj — Wed, 01 Apr 2026 05:58:05 +0000

Novartis has entered into an agreement to acquire biotech firm Excellergy, a move that will bring a next-generation anti-immunoglobulin e (IgE) programme into its pipeline. Excellergy acquisition is structured at up to $2bn in upfront and milestone payments and is expected to close in the second half of 2026, subject to regulatory approvals and customary […]

The post Novartis $2bn Excellergy Acquisition Boosts Allergy Pipeline first appeared on World Pharma Today.

Integrated Drug Development Consulting for Pharmaceuticals

Yuvraj — Mon, 30 Mar 2026 11:41:34 +0000

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

The post Integrated Drug Development Consulting for Pharmaceuticals first appeared on World Pharma Today.